These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34709605)

  • 1. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
    Kristensen LE; Okada M; Tillett W; Leage SL; El Baou C; Sapin C; Bradley AJ; Meszaros G; Dutz JP; de Vlam K
    Rheumatol Ther; 2022 Feb; 9(1):109-125. PubMed ID: 34709605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
    Reich K; Kristensen LE; Smith SD; Rich P; Sapin C; Leage SL; McKenzie R; Schuster C; Riedl E; Gooderham M
    Dermatol Pract Concept; 2022 May; 12(2):e2022104. PubMed ID: 35646453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
    Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
    Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
    Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
    Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
    Armstrong AW; Jaleel T; Merola JF; Gottlieb AB; Khattri S; Helt CC; Malatestinic WN; Ross SE; Ngantcha ME; de Vlam K
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1615-1631. PubMed ID: 38814433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
    Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
    Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
    Kameda H; Hagimori K; Morisaki Y; Holzkämper T; Konomi A; Dobashi H
    Rheumatol Ther; 2023 Dec; 10(6):1683-1703. PubMed ID: 37858007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
    Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
    Coates LC; Kishimoto M; Gottlieb A; Shuler CL; Lin CY; Lee CH; Mease PJ
    RMD Open; 2017; 3(2):e000567. PubMed ID: 29299340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
    McGonagle D; Kavanaugh A; McInnes IB; Kristensen LE; Merola JF; Strober B; Bolce R; Lisse J; Pustizzi J; Sapin C; Ritchlin C
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38341669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Kirkham BW; Egeberg A; Behrens F; Pinter A; Merola JF; Holzkämper T; Gallo G; Ng KJ; Bolce R; Schuster C; Nash P; Puig L
    Rheumatol Ther; 2023 Oct; 10(5):1127-1146. PubMed ID: 37400681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
    Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection.
    Miller J; Puravath AP; Orbai AM
    J Inflamm Res; 2021; 14():6975-6991. PubMed ID: 34949934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.